La enfermedad cardiovascular es una importante causa no sólo de mortalidad, sino también de morbilidad, tanto en los países desarrollados como en aquellos en vías de desarrollo. El síndrome metabólico es un factor de riesgo independiente para la enfermedad cardiovascular. Su presencia aumenta no sólo la prevalencia, sino que también influye en su severidad y pronóstico. Es realmente importante conocer el impacto del síndrome metabólico sobre la morbimortalidad cardiovascular y los factores o nexos de unión entre ellos para planear estrategias de prevención de ámbito poblacional.
Palabras clave
Síndrome metabólico
Enfermedad cardiovascular
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
F.B.J. Villar Álvarez.
Las enfermedades cardiovasculares y sus factores de riesgo en España: hechos y cifras.
Sociedad Española de Arterioesclerosis, (2003),
[2.]
R. Boix, S. Canellas, E. Almazán, C. Cerrato.
Mortalidad cardiovascular en España. Año 2000.
Boletín Epidemiológico Semanal, (2003), 11 pp. 241-252
[3.]
Organizacion Mundial de la Salud. Los objetivos de la salud para todos. Estrategia regional europea. Madrid: OMS; 1986.
[4.]
N. Sattar, A. Gaw, O. Scherbakova, I. Ford, D. O’Reilly, S.M. Haffner, et al.
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.
Circulation, (2003), 108 pp. 414-419
[5.]
S.R. Daniels, D.K. Arnett, R.H. Eckel, S.S. Gidding, L.L. Hayman, S. Kumanyika, et al.
Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment.
Circulation, (2005), 111 pp. 1999-2012
[6.]
A.H. Kissebah, G.R. Krakower.
Regional adiposity and morbidity.
Physiol Rev, (1994), 74 pp. 761-811
[7.]
P.M. Ridker.
High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit.
Am Heart J, (2004), 148 pp. S19-26
[8.]
G. Reaven.
Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease.
Circulation, (2002), 106 pp. 286-288
[9.]
G.L. Vega.
Results of expert meetings: obesity and cardiovascular disease. Obesity, the metabolic syndrome, and cardiovascular disease.
Am Heart J, (2001), 142 pp. 1108-1116
[10.]
A. Zanchetti, L. Hansson, J. Menard, G. Leonetti, K.H. Rahn, I. Warnold, et al.
Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study.
J Hypertens, (2001), 19 pp. 819-825
[11.]
Fruchart JC. International symposium on PPARs (peroxisome proliferator activated receptors): from basic science to clinical applications. Kluwer Academic: Giovanni Lorenzini Medical Foundation; 2002. Medical Science Symposia Series, 18.
[12.]
G. Hu, Q. Qiao, J. Tuomilehto, B. Balkau, K. Borch-Johnsen, K. Pyorala.
Prevalence of the metabolic syndrome and its relation to allcause and cardiovascular mortality in nondiabetic European men and women.
Arch Intern Med, (2004), 164 pp. 1066-1076
[13.]
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
[14.]
H.M. Lakka, D.E. Laaksonen, T.A. Lakka, L.K. Niskanen, E. Kumpusalo, J. Tuomilehto, et al.
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.
JAMA, (2002), 288 pp. 2709-2716
[15.]
B.E. Klein, R. Klein, K.E. Lee.
Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam.
Diabetes Care, (2002), 25 pp. 1790-1794
[16.]
B.C. Solymoss, M.G. Bourassa, L. Campeau, A. Sniderman, M. Marcil, J. Lesperance, et al.
Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity.
Am J Cardiol, (2004), 93 pp. 159-164
[17.]
C.M. Alexander, P.B. Landsman, S.M. Teutsch, S.M. Haffner.
NCEPdefined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older.
Diabetes, (2003), 52 pp. 1210-1214
[18.]
K.E. Kip, O.C. Marroquin, D.E. Kelley, B.D. Johnson, S.F. Kelsey, L.J. Shaw, et al.
Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study.
Circulation, (2004), 109 pp. 706-713
[19.]
J.K. Olijhoek, Y. Van der Graaf, J.D. Banga, A. Algra, T.J. Rabelink, F.L. Visseren.
The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm.
Eur Heart J, (2004), 25 pp. 342-348
[20.]
H.E. Resnick, K. Jones, G. Ruotolo, A.K. Jain, J. Henderson, W. Lu, et al.
Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study.
Diabetes Care, (2003), 26 pp. 861-867
[21.]
A. Hernández Mijares, C. Riera Fortuny, E. Sola Izquierdo, M.J. Oliver Oliver, M.L. Martínez Triguero, C. Morillas Arino, et al.
Prevalencia del síndrome metabólico entre pacientes con cardiopatía isquémica.
Med Clin (Barc), (2003), 121 pp. 204-208
Copyright ©
2005. Sociedad Española de Cardiología